Dissecting PROTAB ‐mediated degradation of cell surface proteins
The FEBS Journal · 10.08.2026
DOI: 10.1111/febs.70670 ↗Kurz gefasst
Fachartikel in der Zeitschrift The FEBS Journal, online erschienen am 10.08.2026. Verfasst von Jieyan He und 7 weiteren Autor:innen. Beteiligte Einrichtung: Biochemical and Cellular Pharmacology, Genentech, 1 DNA Way, South San Francisco, CA, 94080, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
Targeted protein degradation mediated by antibodies has emerged as a promising strategy for degrading extracellular or membrane‐bound proteins. Proteolysis‐Targeting Antibodies (PROTABs) are bispecific antibodies specifically designed to induce the degradation of membrane proteins by tethering them to a cell surface E3 ligase, which promotes ubiquitination and subsequent degradation. Recent studies have demonstrated the potential of PROTABs to degrade oncogenic receptors, but their underlying mechanisms remain to be fully elucidated. Here, we investigated the mechanism of action of a HER2‐targeting PROTAB comprising an anti‐Zinc and RING finger protein 3 (ZNRF3) arm and an anti‐receptor tyrosine‐protein kinase erbB‐2 (HER2) arm. We show that PROTAB induces rapid ternary complex formation, followed by receptor internalization and degradation, resulting in ~ 85% target depletion within 24 h. Mechanistically, ubiquitination enhances but is not strictly required for internalization, and degradation proceeds predominantly through the lysosomal pathway. Notably, ZNRF3 is not codegraded but instead accumulates at the cell surface, while the PROTAB antibody itself is largely recycled. Importantly, target degradation does not consistently translate into growth inhibition, highlighting the role of cellular context and target dependency. Together, these findings provide a mechanistic framework for PROTAB function and inform the rational design of next‐generation antibody‐based degraders.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Biochemical and Cellular Pharmacology, Genentech, 1 DNA Way, South San Francisco, CA, 94080, USA.
- Cell Therapy, Genentech, 1 DNA Way, South San Francisco, CA, 94080, USA.
- Antibody Engineering, Genentech, 1 DNA Way, South San Francisco, CA, 94080, USA.
ORCID-Profile: Wen-Ting K Tsai, Jing Li
Zitieren
APA
He, J., Sun, T., Zhang, M., Sanoyca, A., Tsai, W. K., Kee, Y. S., Agard, N. J., & Li, J. (2026). Dissecting PROTAB ‐mediated degradation of cell surface proteins. The FEBS Journal. https://doi.org/10.1111/febs.70670
Vancouver
He J, Sun T, Zhang M, Sanoyca A, Tsai WK, Kee YS, et al. Dissecting PROTAB ‐mediated degradation of cell surface proteins. The FEBS Journal. 2026. doi:10.1111/febs.70670
BibTeX
@article{He2026,
author = {He, Jieyan and Sun, Tao and Zhang, Mengwen and Sanoyca, Alicia and Tsai, Wen-Ting K and Kee, Yee-Seir and Agard, Nicholas J and Li, Jing},
title = {Dissecting PROTAB ‐mediated degradation of cell surface proteins},
journal = {The FEBS Journal},
year = {2026},
doi = {10.1111/febs.70670}
}
EUVIMED